Lipoprotein (a) as a predictor of XXXX : the PRIME Study.

@entity1 @entity101 @entity6 @entity301 @entity1674 @entity3452 @entity951 @entity583 @entity204 @entity165
The association of an elevated level of lipoprotein (a) ( @entity3452 ) with the development of @entity301 ( @entity301 ) remains controversial. @entity3452 was investigated as a @entity301 risk factor in the PRIME Study, a prospective cohort study which included 9133 French and Northern Irish @entity1 aged 50-59 at entry, without a history of @entity301 and not on hypolipidaemic drugs. During a follow-up of 5 years, 288 subjects experienced at least one @entity301 event ( @entity583 ( @entity583 ), @entity204 , @entity951 ). @entity3452 was measured by immunoassay in all subjects on fresh plasma obtained at entry. Traditional cardiovascular risk factors such as low-density lipoproteins (LDL)- @entity165 , HDL- @entity165 , @entity1674 , the presence of @entity6 , @entity101 or smoking were determined. Logistic regression analysis was used to evaluate @entity3452 level as a @entity301 risk factor after controlling for the other risk factors. In addition, its possible interaction with LDL- and HDL- @entity165 levels was investigated. @entity3452 appeared a significant risk factor (P<0.0006) in the whole cohort without between-population interaction, even if the association was not statistically significant in the Belfast sample. The relative risk (RR) of @entity301 events in subjects with @entity3452 levels in the highest quartile was 1.5 times that of subjects in the lowest quartile (RR: 1.56; 95% confidence intervals (CIs): 1.10-2.21). A high @entity3452 level was a risk for @entity583 , @entity951 . A significant interaction term between @entity3452 and LDL- @entity165 levels, however, was found. The relative @entity301 risk associated with a @entity3452 level > or =33 mg/dl in comparison with @entity3452 <33 mg/dl increasing gradually from 0.82 (95% CI: 0.28-2.44) in @entity1 with LDL- @entity165 in the lowest quartile (<121 mg/dl) to 1.58 (95% CI: 1.06-2.40) in the highest quartile (>163 mg/dl). In conclusion, @entity3452 increased the risk for @entity583 and @entity951 , especially in @entity1 with a high LDL- @entity165 level. This study which analyzed @entity3452 level using a measurement independent of apolipoprotein (a) size on fresh plasma, has confirmed utility of @entity3452 ) as a predictor of @entity301 .
